Quick Win By The Algorithm: NWBO Reassures The Market

Quick Win by the Algorithm

Northwest Biotherapeutics, Inc (NWBO)

On September 21th, 2016, an I Know First analyst had published a pharma stock forecast for the time period of 3 days. In accordance with the algorithms prediction, Northwest Biotherapeutics, Inc had a superb return of 66.43% in just 3 days, causing a quick win by the algorithm.


Northwest Biotherapeutics, Inc. (NWBO) is a biotechnology company developing treatments for cancer patients, such as their product: DCVax.  The company was founded in 1996 and headquartered in Bethesda, Maryland.

The reasoning for Northwest Biotherapeutics Inc.’s exceptional returns over the past few days, is largely due to the NASDAQ Indexes decision to disputes over NWBO’s remediation plan for shares and warrants issued to Cognate Bioservices. Prior to this, NASDAQ had claimed that the firm had failed to comply to certain NASDAQ listing rules. The full disclosure and press release can be found here.

During their peak enrollment period, in july 2013, Northwest Biotherapeutics, Inc. covered their operational expenses with Cognate by issuing equity, as opposed to cash payments. The stock issuance had not been registered correctly and thus did not allow Cognate to monetize on those shares. Thus, the company that is hard strapped for cash, has been able to continue to conduct clinical trial tests without worrying too much about cash expenses and help lift confidence in the stock.


Additional catalysts that have helped the stock rise over the past few days have been news about to receive approximately $1.3 million, after they had reached an agreement with shareholders to convert the warrants of 3.7 million shares into cash for further development.

Both these events have acted as catalysts for the stock price of NWBO and ushered a momentum effect for the share price over the course of the past few days and week as well.

This bullish forecast on NWBO was sent to current I Know First subscribers on September 16th, 2016.